PhRMA: Cures Act Successor Should Include PAHPA, PRV Renewal

Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) and the review voucher program for pediatric rare diseases should be top priorities for future legislation on advancement of biomedical research, as well as policies to combat antimicrobial resistance, according to the drug makers’ lobby Pharmaceutical Research and Manufacturers of America (PhRMA) in a response to Reps. Diana DeGette (D-CO) and Larry Bucshon’s (R-IN) June letter to stakeholders asking for input on new legislation building on the Cures Act.